Evidence map›Paper›PMID 42388797›Full record

ArticlebioRxiv : the preprint server for biology2026

Alveolar niche disruption and aberrant epithelial reprogramming are early hallmarks of idiopathic pulmonary fibrosis.

Aurelien Justet, Venerino Poletti, Cristian Coarfa, Nebal Abu Hussein, Taylor Adams, Alan Waich, Agshin Balayev, Xiting Yan, Zhongyu Cai, Farah Moussa and 22 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Aurelien JustetSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-8639-8667
Venerino PolettiDepartment of Medical Specialties, GB Morgagni Hospital, Forlí, Italy.
Cristian CoarfaCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA.
Nebal Abu HusseinSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Taylor AdamsSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Alan WaichSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Agshin BalayevSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Xiting YanSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0001-8688-9004
Zhongyu CaiSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Farah MoussaUniversité de Caen Normandie, CNRS, Normandie Univ, ISTCT UMR6030, CYCERON, F-14000 CAEN, France.
Ruben De ManSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0001-5468-0281
Johad KhourySection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Jonas C SchuppSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0002-7714-8076
Juan D ZuluagaSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Amy ZhaoSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Julian VillalbaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Farida AhangariSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Scott A OchsnerDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Edward ManningSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.
Wendy J IntroneNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Robert HomerDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Bernadette R GochuicoNational Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Laurens De SadeleerDepartment of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Claudia CarducciDepartment of Clinical and Experimental Medicine, Interventional Pulmonology Unit, Careggi University Hospital, Florence, Italy.
Maria E Ruiz EcharteaCenter for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA.
Chao HeSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Bart M VanaudenaerdeDepartment of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Wim WuytsDepartment of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Claudia RavagliaDepartment of Medical Specialties, GB Morgagni Hospital, Forlí, Italy.
Ivan RosasSection of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Sara TomassettiDepartment of Clinical and Experimental Medicine, Interventional Pulmonology Unit, Careggi University Hospital, Florence, Italy.
Naftali KaminskiSection of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0001-5917-4601

Funding

Genomic Analysis of Tissue and Cellular Heterogeneity in IPFR01HL127349 · NHLBI · YALE UNIVERSITY · PI BENOS, PANAGIOTIS V, KAMINSKI, NAFTALI · 2015 to 2025
$5.9M
Epithelial Protective Effects of Thyroid Hormone Signaling in FibrosisR01HL141852 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$3.4M
Normal Aging Lung Cell Atlas (NALCA)U01HL145567 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2019 to 2022
$2.8M
Novel Biomarkers for Post-Liver Transplant NASH FibrosisR01DK130294 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E, BENOS, PANAGIOTIS V · 2022 to 2025
$2.8M
Mir-29 mimicry as a therapy for pulmonary fibrosisUH2HL123886 · NHLBI · YALE UNIVERSITY · PI KAMINSKI, NAFTALI · 2014 to 2015
$2.7M
Interpretable graphical models for large multi-modal COPD data (R01HL159805)R01HL159805 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BENOS, PANAGIOTIS V, SPIRTES, PETER · 2021 to 2024
$2.0M
Graph Learning of Cell-cell Communications in Spatial TranscriptomicsR01LM014087 · NLM · YALE UNIVERSITY · PI WANG, ZUOHENG, YAN, XITING · 2022 to 2025
$1.5M
Deep and Integrative Analysis of RNA Sequencing Data to Identify Pathogenesis Heterogeneity of Chronic Lung DiseaseR21LM012884 · NLM · YALE UNIVERSITY · PI YAN, XITING · 2018 to 2019
$415k
NHLBI NIH HHS R01 HL127349NHLBI NIH HHS R01 HL141852NHLBI NIH HHS R01 HL159805NHLBI NIH HHS U01 HL145567NHLBI NIH HHS UH2 HL123886NIDDK NIH HHS R01 DK130294NLM NIH HHS R01 LM014087NLM NIH HHS R21 LM012884
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease in which the earliest cellular events driving fibrosis remain poorly defined. Here, we analyzed lung samples from three independent and unique cohorts of patients with early disease and preserved lung function (Florence, NIH, Forli), applying an integrated multi-modal approach combining single-nucleus RNA sequencing, bulk transcriptomics, immunostaining, and spatial transcriptomics. Single nuclear RNA sequencing of samples obtained by diagnostic bronchoscopic cryobiopsy (Florence, n= 22) revealed that early IPF is characterized by a marked shift in alveolar epithelial composition, with loss of AT1 and AT2 cells and the emergence of aberrant basaloid cells and alveolar epithelial intermediate cells. These populations exhibited transcriptional programs associated with epithelial plasticity and profibrotic signaling and closely resembled those observed in end-stage IPF. Higher proportions of aberrant basaloid and alveolar epithelial intermediate cells were associated with subsequent disease progression, whereas AT2 cell abundance correlated with preserved lung function. Fibrotic CTHRC1+ fibroblasts are largely restricted to advanced disease, while endothelial remodeling and inflammatory fibroblast states are already evident in early IPF. Spatial transcriptomic analyses confirmed early disruption of the alveolar niche, with replacement of normal epithelial-capillary interactions by aberrant epithelial and venous endothelial cells (Forli, n= 24); the findings were replicated through single cell RNA sequencing of samples obtained by video assisted thoracoscopy two decades earlier (NIH n=9). Together, these findings identify that alveolar niche remodeling with loss of its normal components, and emergence of aberrant basaloid cells are features of early IPF, highlighting epithelial dysfunction as a key potential target for therapeutic interventions in early disease.

Identifiers

PMID42388797
PMCPMC13317612

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.